BRPI0815067A2 - Compostos de biciclotactama substituída - Google Patents

Compostos de biciclotactama substituída

Info

Publication number
BRPI0815067A2
BRPI0815067A2 BRPI0815067-2A2A BRPI0815067A BRPI0815067A2 BR PI0815067 A2 BRPI0815067 A2 BR PI0815067A2 BR PI0815067 A BRPI0815067 A BR PI0815067A BR PI0815067 A2 BRPI0815067 A2 BR PI0815067A2
Authority
BR
Brazil
Prior art keywords
bicyclestate
compounds
replaced
replaced bicyclestate
bicyclestate compounds
Prior art date
Application number
BRPI0815067-2A2A
Other languages
English (en)
Inventor
Robert Lee Dow
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0815067A2 publication Critical patent/BRPI0815067A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0815067-2A2A 2007-08-02 2008-07-22 Compostos de biciclotactama substituída BRPI0815067A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95350707P 2007-08-02 2007-08-02
PCT/IB2008/001963 WO2009016462A2 (en) 2007-08-02 2008-07-22 Substituted bicyclolactam compounds

Publications (1)

Publication Number Publication Date
BRPI0815067A2 true BRPI0815067A2 (pt) 2015-02-10

Family

ID=39926534

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815067-2A2A BRPI0815067A2 (pt) 2007-08-02 2008-07-22 Compostos de biciclotactama substituída

Country Status (34)

Country Link
US (2) US20090036425A1 (pt)
EP (1) EP2185567B1 (pt)
JP (1) JP4629808B2 (pt)
KR (1) KR20100032443A (pt)
CN (1) CN101772504A (pt)
AP (1) AP2010005163A0 (pt)
AR (1) AR067780A1 (pt)
AT (1) ATE502948T1 (pt)
AU (1) AU2008281545B2 (pt)
BR (1) BRPI0815067A2 (pt)
CA (1) CA2695291C (pt)
CL (1) CL2008002227A1 (pt)
CO (1) CO6251365A2 (pt)
CR (1) CR11223A (pt)
CY (1) CY1111628T1 (pt)
DE (1) DE602008005757D1 (pt)
DK (1) DK2185567T3 (pt)
DO (1) DOP2010000046A (pt)
EA (1) EA201000050A1 (pt)
EC (1) ECSP109932A (pt)
ES (1) ES2361716T3 (pt)
HN (1) HN2008001191A (pt)
HR (1) HRP20110335T1 (pt)
MA (1) MA31580B1 (pt)
PA (1) PA8791601A1 (pt)
PE (1) PE20090897A1 (pt)
PL (1) PL2185567T3 (pt)
PT (1) PT2185567E (pt)
SI (1) SI2185567T1 (pt)
TN (1) TN2010000053A1 (pt)
TW (1) TWI356059B (pt)
UA (1) UA94833C2 (pt)
WO (1) WO2009016462A2 (pt)
ZA (1) ZA201000255B (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
CN101346387A (zh) 2005-12-22 2009-01-14 阿斯利康(瑞典)有限公司 用作DGAT抑制剂的嘧啶并-[4,5-b]-噁嗪
CA2647819C (en) 2006-03-31 2012-12-11 Novartis Ag Phenylcyclohexyl derivatives as dgat1 inhibitors
NZ572586A (en) 2006-05-30 2011-03-31 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AU2007260836B2 (en) 2006-06-23 2012-11-15 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives as histamin H3 receptor modulators
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2010086820A1 (en) * 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
TW201040174A (en) * 2009-02-03 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
JP2012516885A (ja) * 2009-02-04 2012-07-26 ファイザー・インク ４−アミノ−７，８−ジヒドロピリド［４，３−ｄ］ピリミジン−５（６Ｈ）−オン誘導体
EP3366686B9 (en) 2009-03-20 2021-08-04 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
PH12012501800A1 (en) 2010-03-19 2012-12-10 Pfizer 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
WO2011121350A1 (en) 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
NZ609527A (en) 2010-10-29 2014-03-28 Pfizer N1/n2-lactam acetyl-coa carboxylase inhibitors
WO2012112364A1 (en) * 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
WO2012122075A1 (en) * 2011-03-08 2012-09-13 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
AP3499A (en) 2011-04-22 2015-12-31 Pfizer Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EP2707361B1 (en) 2011-05-10 2017-08-23 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
BR112013029935B1 (pt) 2011-05-20 2020-12-15 Glaxosmithkline Intelectual Property (No. 2) Limited Compostos inibidores de diacilglicerol aciltransferase e composição farmacêutica compreende-os
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (pt) 2011-07-01 2018-04-28
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
ES2550345T3 (es) 2011-07-22 2015-11-06 Pfizer Inc. Moduladores del receptor de quinolinilglucagón
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013068439A1 (en) * 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
EP2776405A1 (en) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
US9271969B2 (en) 2012-02-07 2016-03-01 Kainos Medicine, Inc. Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
MA37385B1 (fr) 2012-04-06 2019-09-30 Pfizer Inc Etat De Delaware Inhibiteurs de diacylglycérol-acyltransférase 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP2015520136A (ja) * 2012-04-25 2015-07-16 コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌｔｅｃｈｎｏｌｏｇｙ 新規なベータアラニン誘導体、薬学的に許容される塩、及びそれを有効成分として含有する医薬組成物
EP2852597B1 (en) 2012-05-04 2016-06-08 Pfizer Inc Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2.
IN2014DN09347A (pt) 2012-06-20 2015-07-17 Hoffmann La Roche
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014054053A1 (en) 2012-10-03 2014-04-10 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
SI2922551T1 (sl) * 2012-11-23 2019-05-31 Glaxosmithkline Llc Nove spojine kot inhibitorji diacilglicerol aciltransferaze
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014140241A1 (en) * 2013-03-15 2014-09-18 Intervet International B.V. Pyridine derivatives as dgat-1 inhibitors
CN104418866B (zh) * 2013-08-23 2018-10-16 青岛黄海制药有限责任公司 Dgat1抑制剂及其制备方法和用途
ES2665153T3 (es) 2013-10-09 2018-04-24 Pfizer Inc. Antagonistas del receptor EP3 de prostaglandina
TR201809388T4 (tr) 2014-03-17 2018-07-23 Pfizer Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
HRP20220362T1 (hr) 2014-04-04 2022-05-13 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitori irak4
EA030085B1 (ru) 2014-04-10 2018-06-29 Пфайзер Инк. 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
PE20180503A1 (es) 2015-05-05 2018-03-09 Pfizer 2-tiopirimidinonas
WO2016193844A1 (en) 2015-05-29 2016-12-08 Pfizer Inc. Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
CA2989456C (en) 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
AU2016305590A1 (en) 2015-08-13 2018-02-15 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds
PL3341367T3 (pl) 2015-08-27 2021-07-12 Pfizer Inc. Skondensowane bicyklicznie związki heteroarylowe lub arylowe jako modulatory IRAK4
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
KR102073048B1 (ko) 2015-12-29 2020-02-04 화이자 인코포레이티드 케토헥소키나제 억제제로서의 치환된 3-아자비시클로[3.1.0]헥산
SG11201811161YA (en) 2016-07-14 2019-01-30 Pfizer Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
SG11202101503RA (en) 2018-08-31 2021-03-30 Pfizer Combinations for treatment of nash/nafld and related diseases
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
EP3990452A1 (en) 2019-06-28 2022-05-04 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CN115667250A (zh) 2020-04-29 2023-01-31 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
JP7704982B2 (ja) 2021-12-01 2025-07-08 ファイザー・インク 糖尿病、腎疾患、ｎａｓｈおよび心不全を処置するための分枝鎖アルファケト酸デヒドロゲナーゼキナーゼ阻害剤としての３－フェニル－１－ベンゾチオフェン－２－カルボン酸誘導体
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4598908A1 (en) 2022-10-07 2025-08-13 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
KR20250157491A (ko) 2022-12-15 2025-11-04 가셔브룸 바이오, 인크. Glp-1 효능제 활성을 갖는 화합물의 염 및 고체 형태
CN120731201A (zh) 2022-12-16 2025-09-30 辉瑞公司 含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4417720B2 (ja) * 2002-01-18 2010-02-17 杏林製薬株式会社 縮合二環式ピリミジン誘導体
MXPA05005425A (es) * 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
CA2554455A1 (en) * 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic
JP2006056881A (ja) * 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
CN101346387A (zh) 2005-12-22 2009-01-14 阿斯利康(瑞典)有限公司 用作DGAT抑制剂的嘧啶并-[4,5-b]-噁嗪

Also Published As

Publication number Publication date
UA94833C2 (en) 2011-06-10
US7718645B2 (en) 2010-05-18
TN2010000053A1 (fr) 2011-09-26
EP2185567A2 (en) 2010-05-19
ATE502948T1 (de) 2011-04-15
DE602008005757D1 (de) 2011-05-05
WO2009016462A3 (en) 2009-03-26
CY1111628T1 (el) 2015-10-07
AU2008281545B2 (en) 2011-12-08
CA2695291C (en) 2012-04-17
US20090137551A1 (en) 2009-05-28
AR067780A1 (es) 2009-10-21
PA8791601A1 (es) 2009-12-16
ZA201000255B (en) 2011-03-30
EP2185567B1 (en) 2011-03-23
SI2185567T1 (sl) 2011-06-30
PT2185567E (pt) 2011-05-27
CR11223A (es) 2010-02-04
CA2695291A1 (en) 2009-02-05
MA31580B1 (fr) 2010-08-02
ECSP109932A (es) 2010-03-31
US20090036425A1 (en) 2009-02-05
DOP2010000046A (es) 2010-03-31
EA201000050A1 (ru) 2010-08-30
JP2010535190A (ja) 2010-11-18
KR20100032443A (ko) 2010-03-25
ES2361716T3 (es) 2011-06-21
WO2009016462A2 (en) 2009-02-05
TW200916471A (en) 2009-04-16
PL2185567T3 (pl) 2011-07-29
CN101772504A (zh) 2010-07-07
JP4629808B2 (ja) 2011-02-09
AP2010005163A0 (en) 2010-02-28
AU2008281545A1 (en) 2009-02-05
PE20090897A1 (es) 2009-08-06
DK2185567T3 (da) 2011-05-16
HRP20110335T1 (hr) 2011-06-30
CO6251365A2 (es) 2011-02-21
TWI356059B (en) 2012-01-11
CL2008002227A1 (es) 2009-04-17
HN2008001191A (es) 2012-01-17

Similar Documents

Publication Publication Date Title
BRPI0815067A2 (pt) Compostos de biciclotactama substituída
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
BRPI0818380A2 (pt) Combinação de herbicida-protetor
EP2170350A4 (en) SUBSTITUTED IMIDAZOHETEROCYCLES
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0815717A2 (pt) Compostos de imidazopirazina.
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
BRPI0811264A2 (pt) Compostos
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
BRPI0809996A2 (pt) Compostos
BRPI0806537A2 (pt) Indazóis substituídos por 5-piridinona
BRPI0811939A2 (pt) Tiazóis substituídos por heteroarila
BRPI0814424A2 (pt) Compostos heterociclila
DK2297162T3 (da) Forbindelser
BRPI0816512A2 (pt) Cartucho de tinta
BRPI0817149A2 (pt) Cartucho de tinta
BRPI0916432A2 (pt) compostos
BRPI0806506A2 (pt) Indazóis substituídos por 5-furopiridinona
BRPI0815181A2 (pt) Compostos
PT2792662T (pt) Compostos de morfinano
DK2206698T3 (da) Ethynylindolforbindelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.